Kintara Therapeutics, Inc. Announces Board Changes
May 03, 2021 at 02:05 pm
Share
Kintara Therapeutics, Inc. announced that on April 29, 2021, Tamara A. Seymour was appointed to the Board of Directors of the Company. In connection with Ms. Seymour’s appointment, John Liatos submitted his resignation from the Board, effective as of April 29, 2021. Mr. Liatos’s resignation was not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Mr. Liatos will continue in his role as Senior Vice President of Business Development of the Company. Ms. Seymour has served as a member of the board of directors and audit committee of Artelo Biosciences, Inc., since March 2021. Previously, she served as a member of the board of directors and Chair of the audit committee of Beacon Discovery, Inc., from September 2018 until its acquisition by Eurofins Scientific in March 2021. Ms. Seymour served as Interim Chief Financial Officer of Immunic, Inc. from April 2019 to August 2019. She was Chief Financial Officer of Signal Genetics, Inc, from August 2014 to February 2017. Ms. Seymour will serve as a director on the Board until the 2021 annual meeting of the Company’s stockholders or until her successor is elected and qualified, subject to her earlier resignation or removal.
Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.